LUZP1, a novel regulator of primary cilia and the actin cytoskeleton, is a contributing factor in Townes-Brocks Syndrome
- CIC bioGUNE, Spain
- Achucarro Basque Center for Neuros, Spain
- University of the Basque Country (UPV/EHU), Spain
- Stanford University, United States
Abstract
Primary cilia are sensory organelles crucial for cell signaling during development and organ homeostasis. Cilia arise from centrosomes and their formation and function is governed by numerous factors. Through our studies on Townes-Brocks Syndrome (TBS), a rare disease linked to abnormal cilia formation in human fibroblasts, we uncovered the leucine-zipper protein LUZP1 as an interactor of truncated SALL1, a dominantly-acting protein causing the disease. Using TurboID proximity labeling and pulldowns, we show that LUZP1 associates with factors linked to centrosome and actin filaments. Here, we show that LUZP1 is a cilia regulator. It localizes around the centrioles and to actin cytoskeleton. Loss of LUZP1 reduces F-actin levels, facilitates ciliogenesis and alters Sonic Hedgehog signaling, pointing to a key role in cytoskeleton-cilia interdependency. Truncated SALL1 increases the ubiquitin proteasome-mediated degradation of LUZP1. Together with other factors, alterations in LUZP1 may be contributing to TBS etiology.
Data availability
All data generated or analysed during this study are included in the manuscript and supporting files.
Article and author information
Author details
Funding
Ministerio de Economía y Competitividad (BFU2017-84653-P)
- Rosa Barrio
Asociacion Espanola Contra el Cancer (IDEAS175CARR)
- Arkaitz Carracedo
Asociacion Espanola Contra el Cancer (GCTRA18006CARR)
- Arkaitz Carracedo
La Caixa Foundation (HR17-00094)
- Arkaitz Carracedo
European Commission (336343)
- Arkaitz Carracedo
European Commission (PoC 754627)
- Arkaitz Carracedo
European Commission (819242)
- Arkaitz Carracedo
Ministerio de Economía y Competitividad (SEV-2016-0644)
- Arkaitz Carracedo
- Felix Elortza
- James D Sutherland
- Rosa Barrio
Ministerio de Economía y Competitividad (SAF2017-90900-REDT)
- Rosa Barrio
European Commission (765445-EU)
- Orhi Barroso-Gomila
- James D Sutherland
- Rosa Barrio
Basque Government (IT634-13)
- Arkaitz Carracedo
Asociacion Espanola Contra el Cancer (POSTD19048BOZA)
- Arkaitz Carracedo
Instituto de Salud Carlos III (PT13/0001/0027)
- Arkaitz Carracedo
Basque Government (IKERTALDE IT1106-16)
- Arkaitz Carracedo
Ministerio de Ciencia, Investigacion y Universidades (SAF2016-79381-R)
- Arkaitz Carracedo
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- Lotte Pedersen, University of Copenhagen, Denmark
Ethics
Human subjects: The use of human samples in this study was approved by the institutional review board (Ethics Committee at CIC bioGUNE) and appropriate informed consent was obtained from human subjects or their parents. protocol P-CBG-CBBA-2111)
Version history
- Received: February 12, 2020
- Accepted: June 18, 2020
- Accepted Manuscript published: June 18, 2020 (version 1)
- Version of Record published: July 15, 2020 (version 2)
Copyright
© 2020, Bozal-Basterra et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 3,591
- views
-
- 554
- downloads
-
- 29
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
LUZP1, a novel regulator of primary cilia and the actin cytoskeleton, is a contributing factor in Townes-Brocks Syndrome
eLife 9:e55957.
https://doi.org/10.7554/eLife.55957
Further reading
-
- Cancer Biology
- Cell Biology
High-throughput vertebrate animal model systems for the study of patient-specific biology and new therapeutic approaches for aggressive brain tumors are currently lacking, and new approaches are urgently needed. Therefore, to build a patient-relevant in vivo model of human glioblastoma, we expressed common oncogenic variants including activated human EGFRvIII and PI3KCAH1047R under the control of the radial glial-specific promoter her4.1 in syngeneic tp53 loss-of-function mutant zebrafish. Robust tumor formation was observed prior to 45 days of life, and tumors had a gene expression signature similar to human glioblastoma of the mesenchymal subtype, with a strong inflammatory component. Within early stage tumor lesions, and in an in vivo and endogenous tumor microenvironment, we visualized infiltration of phagocytic cells, as well as internalization of tumor cells by mpeg1.1:EGFP+ microglia/macrophages, suggesting negative regulatory pressure by pro-inflammatory cell types on tumor growth at early stages of glioblastoma initiation. Furthermore, CRISPR/Cas9-mediated gene targeting of master inflammatory transcription factors irf7 or irf8 led to increased tumor formation in the primary context, while suppression of phagocyte activity led to enhanced tumor cell engraftment following transplantation into otherwise immune-competent zebrafish hosts. Altogether, we developed a genetically relevant model of aggressive human glioblastoma and harnessed the unique advantages of zebrafish including live imaging, high-throughput genetic and chemical manipulations to highlight important tumor-suppressive roles for the innate immune system on glioblastoma initiation, with important future opportunities for therapeutic discovery and optimizations.
-
- Cancer Biology
- Cell Biology
Establishing a zebrafish model of a deadly type of brain tumor highlights the role of the immune system in the early stages of the disease.
